2006
DOI: 10.1007/s00280-005-0176-3 View full text |Buy / Rent full text
|
|

Abstract: The chemoradiation regimen tested in this study has promising activity and manageable toxicity. The continuous schedule could not be recommended due to excessive toxicity. The main DLT was esophagitis, and it significantly correlated with the plasma AAG concentration.

Help me understand this report

Search citation statements

Order By: Relevance
Select...
2
0
2
0

Year Published

2010
2010
2012
2012

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

0
2
0
Order By: Relevance
“…Non-small cell lung cancer (NSCLC) is the most prevalent type of lung cancer. The treatment of choice for loco-regional and advanced NSCLC is concurrent chemoradiation therapy (CXRT) (Jemal et al, 2009; Yamamoto et al, 2006), a modality that is frequently associated with multiple symptoms induced by accumulating doses of radiation and chemotherapy (Wang et al, 2006). …”
Section: Introductionmentioning
Create an account to read the remaining citation statements from this report. You will also get access to:
  • Search over 1.2b+ citation statments to see what is being said about any topic in the research literature
  • Advanced Search to find publications that support or contrast your research
  • Citation reports and visualizations to easily see what publications are saying about each other
  • Browser extension to see Smart Citations wherever you read research
  • Dashboards to evaluate and keep track of groups of publications
  • Alerts to stay on top of citations as they happen
  • Automated reference checks to make sure you are citing reliable research in your manuscripts
  • 14 day free preview of our premium features.

Trusted by researchers and organizations around the world

Over 130,000 students researchers, and industry experts at use scite

See what students are saying

rupbmjkragerfmgwileyiopcupepmcmbcthiemesagefrontiersapsiucrarxivemeralduhksmucshluniversity-of-gavle
“…Non-small cell lung cancer (NSCLC) is the most prevalent type of lung cancer. The treatment of choice for loco-regional and advanced NSCLC is concurrent chemoradiation therapy (CXRT) (Jemal et al, 2009; Yamamoto et al, 2006), a modality that is frequently associated with multiple symptoms induced by accumulating doses of radiation and chemotherapy (Wang et al, 2006). …”
Section: Introductionmentioning
“…At the initiation of this study, cisplatin-docetaxel combined with concurrent radiation in patients with stage IIIA/B NSCLC showed encouraging results with good response rates and grade 3 esophagitis as the main dose-limiting toxicity. The recommended weekly dose was 20–25 mg/m 2 docetaxel and cisplatin with concurrent standard radiation in most phase I trials [16,17,18]. Otherwise, it has been demonstrated that 4–6 cycles with full doses of chemotherapy are necessary for effectiveness in advanced NSCLC [19].…”
Section: Introductionmentioning